Next Article in Journal / Special Issue
Neural Invasion in Pancreatic Cancer: The Past, Present and Future
Previous Article in Journal
YKL-40—A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients?
Previous Article in Special Issue
Serum Tumor Markers in Pancreatic Cancer—Recent Discoveries
Cancers 2010, 2(3), 1492-1512; doi:10.3390/cancers2031492
Review

The Kinase Mirk/dyrk1B: A Possible Therapeutic Target in Pancreatic Cancer

Received: 26 May 2010; in revised form: 28 June 2010 / Accepted: 8 July 2010 / Published: 14 July 2010
(This article belongs to the Special Issue Pancreatic Cancer)
View Full-Text   |   Download PDF [3761 KB, uploaded 14 July 2010]   |   Browse Figures
Abstract: Pancreatic ductal adenocarcinomas are strongly resistant to chemotherapeutic drugs and radiation, underscoring the need for new therapeutic targets, particularly ones which target the numerous out of cycle cancer cells. Analysis of resected tumors for nuclear Ki67 antigen has shown that about 70% of pancreatic cancer cells are out of cycle, some post-mitotic. Other out of cycle cells are in a quiescent, reversible G0 state, resistant to drugs which target dividing cells, with some able to repopulate a tumor. The serine/threonine kinase Mirk/dyrk1B is a downstream effector of oncogenic K-ras, the most common mutation in this cancer. Mirk expression is elevated in quiescent pancreatic cancer cells and mediates their prolonged survival through increasing expression of a cohort of antioxidant genes. Mirk is expressed in about 90% of pancreatic cancers and is amplified in a subset. Mirk appears not to be an essential gene for normal cells from embryonic knockout studies in mice and RNA interference studies on cultured cells, but is upregulated in pancreatic tumor cells. These unusual characteristics suggest that Mirk may be a selective target for therapeutic intervention.
Keywords: Mirk; Dyrk; reactive oxygen species (ROS); K-ras Mirk; Dyrk; reactive oxygen species (ROS); K-ras
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Friedman, E. The Kinase Mirk/dyrk1B: A Possible Therapeutic Target in Pancreatic Cancer. Cancers 2010, 2, 1492-1512.

AMA Style

Friedman E. The Kinase Mirk/dyrk1B: A Possible Therapeutic Target in Pancreatic Cancer. Cancers. 2010; 2(3):1492-1512.

Chicago/Turabian Style

Friedman, Eileen. 2010. "The Kinase Mirk/dyrk1B: A Possible Therapeutic Target in Pancreatic Cancer." Cancers 2, no. 3: 1492-1512.


Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert